8-K Announcements
6Material company update
Apr 28, 2026·SEC
Material company update
Nov 4, 2025·SEC
Material company update
Oct 28, 2025·SEC
Nautilus Biotechnology, Inc.(NAUT)Earnings, Financials & Key Ratios
NAUT•NASDAQ
$2.94
$374M mkt cap·Price updated May 6, 2026
AboutNautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.Show more
- Revenue$0
- EBITDA-$60M+19.6%
- Net Income-$59M+16.6%
- EPS (Diluted)-0.47+16.1%
- ROE-32.27%-8.1%
- ROIC-25.96%-4.5%
- Debt/Equity0.19+31.0%
NAUT Key Insights
Nautilus Biotechnology, Inc. (NAUT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 95 (top 5%)
✗Weaknesses
- ✗Profits declining 30.4% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
NAUT Price & Volume
Nautilus Biotechnology, Inc. (NAUT) stock price & volume — 10-year historical chart
Loading chart...
NAUT Growth Metrics
Nautilus Biotechnology, Inc. (NAUT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM16.86%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM14.81%
Return on Capital
10 Years-30.67%
5 Years-25%
3 Years-28.81%
Last Year-31.96%
NAUT Recent Earnings
Nautilus Biotechnology, Inc. (NAUT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 12/12 qtrs (100%)
Q2 2026Latest
Apr 28, 2026EPS
$0.12
Est $0.14
+17.2%
Revenue
—
Est $250,000
Q1 2026
Feb 26, 2026EPS
$0.11
Est $0.14
+21.4%
Revenue
—
Est $1M
Q4 2025
Oct 27, 2025EPS
$0.11
Est $0.15
+26.7%
Revenue
—
Q3 2025
Jul 31, 2025EPS
$0.12
Est $0.15
+22.6%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 28, 2026 | $0.12vs $0.14+17.2% | —vs $250,000 |
| Q1 2026 | Feb 26, 2026 | $0.11vs $0.14+21.4% | —vs $1M |
| Q4 2025 | Oct 27, 2025 | $0.11vs $0.15+26.7% | — |
| Q3 2025 | Jul 31, 2025 | $0.12vs $0.15+22.6% | — |
Based on last 12 quarters of dataView full earnings history →
NAUT Peer Comparison
Nautilus Biotechnology, Inc. (NAUT) competitors in Diagnostics and Omics Tools — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CDNA | 1.08B | 20.94 | -52.35 | 13.79% | -1.98% | -2.61% | 0.06 | |
 SEER | 105.44M | 1.89 | -1.36 | -8.13% | -486.02% | -29.19% | 0.08 | |
 QBTS | 8.48B | 23.84 | -21.48 | 178.54% | -14.44% | -41.66% | 0.01 | |
 ILMN | 21.66B | 142.58 | 26.16 | -0.78% | 19.43% | 32.84% | 0.94 | |
 PACB | 516.17M | 1.71 | -1.60 | -23.19% | -325.8% | -13.95% | 1.33 | |
 BFLY | 1.19B | 4.55 | -14.68 | 18.96% | -73.63% | -36.79% | 0.10 | |
 TWST | 3.71B | 59.53 | -45.79 | 20.32% | -19.85% | -17.46% | 0.29 | |
 BEAM | 3.32B | 32.33 | -39.92 | 120.01% | -57.24% | -7.31% | 0.24 |
Compare NAUT vs Peers
Nautilus Biotechnology, Inc. (NAUT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NAUT Income Statement
Nautilus Biotechnology, Inc. (NAUT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 2.35M | 2.84M | 3.42M | 5.71M | 6.35M | 6.46M | 6.32M |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | -2.35M▲ 0% | -2.84M▼ 21.1% | -3.42M▼ 20.2% | -5.71M▼ 67.0% | -6.35M▼ 11.4% | -6.46M▼ 1.8% | -6.32M▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | -21.14% | -20.2% | -67.01% | -11.36% | -1.76% | - |
| Operating Expenses | 111.68M | 10.11M | 13.4M | 47.66M | 60.2M | 70.45M | 75.12M | 60.37M | 59.28M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 111.68M | 1.62M | 3.31M | 21.15M | 23.75M | 28.9M | 31M | 25.73M | 22.47M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
| Research & Development | 0 | 8.49M | 10.09M | 26.51M | 36.45M | 47.25M | 50.48M | 41.11M | 39.75M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | -5.71M | -6.35M | -6.46M | -1000K |
| Operating Income | -111.68M▲ 0% | -10.11M▲ 90.9% | -15.74M▼ 55.7% | -50.5M▼ 220.7% | -63.62M▼ 26.0% | -76.15M▼ 19.7% | -81.48M▼ 7.0% | -66.84M▲ 18.0% | -64.12M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | 90.95% | -55.73% | -220.74% | -25.98% | -19.7% | -6.99% | 17.97% | - |
| EBITDA | 626.6M | -9.56M | -13.4M | -47.66M | -60.2M | -74.3M | -75.12M | -60.37M | -57.8M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | - | -101.53% | -40.12% | -255.69% | -26.33% | -23.42% | -1.1% | 19.64% | 14.4% |
| D&A (Non-Cash Add-back) | 738.28M | 548K | 2.35M | 2.84M | 3.42M | 1.85M | 6.35M | 6.46M | 6.32M |
| EBIT | -111.68M | -10.11M | -15.62M | -50.31M | -57.92M | -76.15M | -70.78M | -59M | -58.51M |
| Net Interest Income | 0 | 0 | 0 | 329K | 0 | 12.55M | 10.78M | 7.87M | 7.08M |
| Interest Income | 0 | 0 | 0 | 329K | 5.82M | 12.55M | 10.78M | 7.87M | 7.08M |
| Interest Expense | 0 | 0 | 0 | 0 | 5.82M | 0 | 0 | 0 | 0 |
| Other Income/Expense | 738.28M | 492K | 125K | 183K | 5.69M | 12.48M | 10.7M | 7.84M | 7.03M |
| Pretax Income | 626.6M▲ 0% | -9.62M▼ 101.5% | -15.62M▼ 62.4% | -50.31M▼ 222.1% | -57.92M▼ 15.1% | -63.67M▼ 9.9% | -70.78M▼ 11.2% | -59M▲ 16.6% | -57.09M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | 626.6M▲ 0% | -9.62M▼ 101.5% | -15.62M▼ 62.4% | -50.31M▼ 222.1% | -57.92M▼ 15.1% | -63.67M▼ 9.9% | -70.78M▼ 11.2% | -59M▲ 16.6% | -57.09M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | - | -101.53% | -62.39% | -222.14% | -15.12% | -9.93% | -11.16% | 16.64% | 16.86% |
| Net Income (Continuing) | 626.6M | -9.62M | -15.62M | -50.31M | -57.92M | -63.67M | -70.78M | -59M | -57.09M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 87.18▲ 0% | -1.59▼ 101.8% | -0.47▲ 70.4% | -0.60▼ 27.7% | -0.46▲ 23.3% | -0.51▼ 10.9% | -0.56▼ 9.8% | -0.47▲ 16.1% | -0.45▲ 0% |
| EPS Growth % | - | -101.82% | 70.44% | -27.66% | 23.33% | -10.87% | -9.8% | 16.07% | 14.81% |
| EPS (Basic) | 87.18 | -1.59 | -0.47 | -0.60 | -0.46 | -0.51 | -0.56 | -0.47 | - |
| Diluted Shares Outstanding | 7.19M | 6.07M | 33.07M | 84.46M | 124.59M | 124.92M | 125.43M | 126.26M | 126.63M |
| Basic Shares Outstanding | 7.19M | 6.07M | 33.07M | 84.46M | 124.59M | 124.92M | 125.43M | 126.26M | 126.63M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
NAUT Balance Sheet
Nautilus Biotechnology, Inc. (NAUT) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 1.33M | 16.96M | 77.66M | 349.22M | 187.21M | 176.84M | 132.83M | 105.96M | 98.83M |
| Cash & Short-Term Investments | 144.49B | 16.66M | 76.74M | 345.73M | 184.47M | 173.42M | 129.89M | 103.41M | 95.87M |
| Cash Only | 1.2M | 595K | 36.61M | 185.62M | 114.52M | 19.4M | 27.65M | 12.39M | 14.63M |
| Short-Term Investments | 144.49B | 16.06M | 40.13M | 160.11M | 69.95M | 154.02M | 102.25M | 91.02M | 81.24M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | -144.49B | 0 | 0 | 0 | 0 | 3.42M | 2.93M | 2.56M | 2.96M |
| Total Non-Current Assets | 144.49M | 1.58M | 7.35M | 49.23M | 162.84M | 128.73M | 109.92M | 85.15M | 78.95M |
| Property, Plant & Equipment | 0 | 1.12M | 6.21M | 31.86M | 32.57M | 36.9M | 32.33M | 31.23M | 30.27M |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 144.49M | 0 | 0 | 16.37M | 129.17M | 90.65M | 76.41M | 52.74M | 168.94M |
| Other Non-Current Assets | 0 | 459K | 1.14M | 997K | 1.11M | 1.18M | 1.18M | 1.18M | 4.72M |
| Total Assets | 145.82M▲ 0% | 18.54M▼ 87.3% | 85.01M▲ 358.5% | 398.45M▲ 368.7% | 350.05M▼ 12.1% | 305.56M▼ 12.7% | 242.74M▼ 20.6% | 191.11M▼ 21.3% | 177.78M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | - | 0.00x |
| Asset Growth % | - | -87.28% | 358.48% | 368.7% | -12.15% | -12.71% | -20.56% | -21.27% | -87.66% |
| Total Current Liabilities | 5K | 490K | 3.02M | 5.81M | 6.79M | 9.12M | 7.63M | 7.95M | 8.34M |
| Accounts Payable | 0 | 289K | 470K | 1.72M | 1.27M | 1.64M | 987K | 943K | 1.19M |
| Days Payables Outstanding | - | - | 73.12 | 221.29 | 135.91 | 104.86 | 56.71 | 53.24 | 57.73 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.83M | 3.85M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 5K | 77K | 617K | 388K | 438K | 2.97M | 2.55M | 3.18M | 3.31M |
| Current Ratio | 266.45x | 34.62x | 25.73x | 60.09x | 27.57x | 19.39x | 17.40x | 13.33x | 13.33x |
| Quick Ratio | 266.45x | 34.62x | 25.73x | 60.09x | 27.57x | 19.39x | 17.40x | 13.33x | 13.33x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 5M | 275M | 111.71M | 29.06M | 28.34M | 31.09M | 26.38M | 26.19M | 25.02M |
| Long-Term Debt | 5M | 275M | 0 | 0 | 0 | 0 | 0 | 26.19M | 25.02M |
| Capital Lease Obligations | 0 | 0 | 3.3M | 29.06M | 28.34M | 31.09M | 26.38M | 0 | 46.75M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 108.42M | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 140.82M | 490K | 114.73M | 34.87M | 35.13M | 40.21M | 34.01M | 34.14M | 33.36M |
| Total Debt | 5M | 275M | 4.78M | 30.03M | 30.33M | 34.63M | 30.48M | 30.02M | 28.87M |
| Net Debt | 3.8M | 274.4M | -31.83M | -155.59M | -84.19M | 15.23M | 2.83M | 17.63M | 14.25M |
| Debt / Equity | 1.00x | 15.23x | - | 0.08x | 0.10x | 0.13x | 0.15x | 0.19x | 0.19x |
| Debt / EBITDA | 0.01x | - | - | - | - | - | - | - | -0.50x |
| Net Debt / EBITDA | 0.01x | - | - | - | - | - | - | - | -0.25x |
| Interest Coverage | - | - | - | - | -9.96x | - | - | - | - |
| Total Equity | 5M▲ 0% | 18.05M▲ 261.0% | -29.72M▼ 264.6% | 363.58M▲ 1323.3% | 314.92M▼ 13.4% | 265.35M▼ 15.7% | 208.73M▼ 21.3% | 156.97M▼ 24.8% | 144.41M▲ 0% |
| Equity Growth % | - | 261.04% | -264.64% | 1323.3% | -13.38% | -15.74% | -21.34% | -24.8% | -97.85% |
| Book Value per Share | 0.70 | 2.98 | -0.90 | 4.30 | 2.53 | 2.12 | 1.66 | 1.24 | 1.14 |
| Total Shareholders' Equity | 5M | 18.05M | -29.72M | 363.58M | 314.92M | 265.35M | 208.73M | 156.97M | 144.41M |
| Common Stock | 0 | 1K | 1K | 12K | 12K | 13K | 13K | 13K | 13K |
| Retained Earnings | 626.6K | -14.71M | -30.32M | -80.64M | -138.56M | -202.24M | -273.02M | -332.02M | -346.72M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 7K | 3K | -184K | -1.85M | -255K | 57K | 243K | -91K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NAUT Cash Flow Statement
Nautilus Biotechnology, Inc. (NAUT) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -238.3M | -9.66M | -14M | -39.24M | -45.81M | -51.71M | -59.15M | -50.7M | -50.7M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | - | 95.95% | -44.86% | -180.37% | -16.73% | -12.89% | -14.38% | 14.29% | 49.01% |
| Net Income | 626.6M | -9.62M | -15.62M | -50.31M | -57.92M | -63.67M | -70.78M | -59M | -57.09M |
| Depreciation & Amortization | 0 | 548K | 2.35M | 2.84M | 3.42M | 5.71M | 6.35M | 6.46M | 6.32M |
| Stock-Based Compensation | 0 | 110K | 369K | 7.93M | 10.38M | 12.14M | 12.7M | 6.84M | 6.04M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -866.23M | -157K | 295K | 320K | -890K | -2.66M | -1.96M | -1.42M | -947K |
| Working Capital Changes | 1.33M | -545K | -1.39M | -22K | -788K | -3.22M | -5.46M | -3.58M | -4.18M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 123K | 1.26M | -561K | 393K | -578K | -69K | 262K |
| Cash from Investing | 1.2M | 4.05M | -25.28M | -138.96M | -25.74M | -43.73M | 66.25M | 35.22M | 29.95M |
| Capital Expenditures | 0 | -926K | -921K | -2.27M | -2.32M | -2.44M | -2.12M | -1.28M | -1.57M |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 1.2M | 4.98M | 0 | 0 | 0 | 0 | 154.65M | 0 | -11.13M |
| Cash from Financing | 145.19B | 36K | 75.9M | 327.45M | 562K | 368K | 1.14M | 214K | 1.3M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 75.86M | -7.96M | 562K | 368K | 1.14M | 214K | 1.3M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -1.2M | -874.33K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 145.19B | 36K | 42K | 335.41M | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 1.2M▲ 0% | 595K▼ 50.3% | 36.62M▲ 6055.3% | 149.24M▲ 307.5% | -70.98M▼ 147.6% | -95.08M▼ 33.9% | 8.25M▲ 108.7% | -15.26M▼ 285.0% | -18.61M▲ 0% |
| Free Cash Flow | -238.3M▲ 0% | -10.59M▲ 95.6% | -14.92M▼ 40.9% | -41.51M▼ 178.3% | -48.13M▼ 15.9% | -54.15M▼ 12.5% | -61.27M▼ 13.1% | -51.97M▲ 15.2% | -51.43M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | - | - |
| FCF Growth % | - | 95.56% | -40.89% | -178.27% | -15.95% | -12.51% | -13.14% | 15.17% | 12.11% |
| FCF per Share | -33.15 | -1.75 | -0.45 | -0.49 | -0.39 | -0.43 | -0.49 | -0.41 | -0.41 |
| FCF Conversion (FCF/Net Income) | -0.38x | 1.00x | 0.90x | 0.78x | 0.79x | 0.81x | 0.84x | 0.86x | 0.90x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NAUT Key Ratios
Nautilus Biotechnology, Inc. (NAUT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -83.45% | - | -30.14% | -17.07% | -21.95% | -29.86% | -32.27% | -35.04% |
| Return on Invested Capital (ROIC) | -5.03% | -10.23% | -51.73% | -21.75% | -22.34% | -24.83% | -25.96% | -25.96% |
| Debt / Equity | 15.23x | - | 0.08x | 0.10x | 0.13x | 0.15x | 0.19x | 0.19x |
| Interest Coverage | - | - | - | -9.96x | - | - | - | - |
| FCF Conversion | 1.00x | 0.90x | 0.78x | 0.79x | 0.81x | 0.84x | 0.86x | 0.90x |
NAUT SEC Filings & Documents
Nautilus Biotechnology, Inc. (NAUT) SEC filings — annual & quarterly reports (10-K, 10-Q)
NAUT Frequently Asked Questions
Nautilus Biotechnology, Inc. (NAUT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Nautilus Biotechnology, Inc. (NAUT) grew revenue by 0.0% over the past year. Growth has been modest.
Nautilus Biotechnology, Inc. (NAUT) reported a net loss of $57.1M for fiscal year 2025.
Dividend & Returns
Nautilus Biotechnology, Inc. (NAUT) has a return on equity (ROE) of -32.3%. Negative ROE indicates the company is unprofitable.
Nautilus Biotechnology, Inc. (NAUT) had negative free cash flow of $51.4M in fiscal year 2025, likely due to heavy capital investments.
Explore More NAUT
Nautilus Biotechnology, Inc. (NAUT) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates